Q-omics provides the consensus-scored ASB17 profile across patient tissues and cancer cell-line models. ASB17 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ASB17 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, ASB17 RNA expression shows 6,531 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, KICH, and STAD as cancer lineages where ASB17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASB17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASB17 survival associations across molecular data types. ASB17 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASB17 RNA expression–survival associations across cancer types. High ASB17 expression shows unfavorable associations in MESO, BRCA, THYM, UCS and ACC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ASB17 RNA expression.
This table summarizes ASB17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ASB17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASB17 shows lower tumor expression in KICH and KIRP and higher tumor expression in UCEC, LUAD and LIHC. The KICH box plot shows higher ASB17 RNA expression in normal versus tumor tissue (log2 FC = −0.317, t-test p < 0.001).
This table shows molecular features associated with ASB17 in patient tissues and cancer cell lines. In patient samples, ASB17 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ASB17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
